64 related articles for article (PubMed ID: 31621912)
1. Identification of lncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancer.
Quan D; Chen K; Zhang J; Guan Y; Yang D; Wu H; Wu S; Lv L
J Cell Physiol; 2020 Apr; 235(4):3372-3381. PubMed ID: 31621912
[TBL] [Abstract][Full Text] [Related]
2. Circular RNA circPRMT5 is upregulated in breast cancer and is required for cell proliferation and migration.
Li X; Zhang D; Feng Z; Xu X; Zhang J; Yu A; Zhu L; Xiao J; Du J; Chen M
Turk J Med Sci; 2022 Apr; 52(2):303-312. PubMed ID: 36161608
[TBL] [Abstract][Full Text] [Related]
3. Insights into the Crosstalk Between miR-200a/lncRNA H-19 and IL-6/SIRT-1 Axis in Breast Cancer.
Khalil M; Desouky EM; Khaliefa AK; Hozyen WG; Mohamed SS; Hasona NA
J Interferon Cytokine Res; 2024 May; 44(5):191-197. PubMed ID: 38466957
[TBL] [Abstract][Full Text] [Related]
4. Decoding LINC00052 role in breast cancer by bioinformatic and experimental analyses.
Sanchez-Lopez JM; Juarez-Mancera MA; Bustamante B; Ruiz-Silvestre A; Espinosa M; Mendoza-Almanza G; Ceballos-Cancino G; Melendez-Zajgla J; Maldonado V; Lizarraga F
RNA Biol; 2024 Jan; 21(1):1-11. PubMed ID: 38832821
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of DHCR7 as a diagnostic biomarker involved in the proliferation and mitochondrial function of breast cancer.
Wang Y; Fan J; Liu Y; Du J; Liang B; Wang H; Song Z
Aging (Albany NY); 2024 Mar; 16(7):5967-5986. PubMed ID: 38526324
[TBL] [Abstract][Full Text] [Related]
6. ASSOCIATION OF miRNA EXPRESSION PATTERN WITH OUTCOME OF LETROZOLE THERAPY IN BREAST CANCER PATIENTS.
Pridko O; Borikun T; Rossylna O; Rusyn AV
Exp Oncol; 2023 Oct; 45(2):180-186. PubMed ID: 37824774
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.
Zhan Y; Jiang L; Jin X; Ying S; Wu Z; Wang L; Yu W; Tong J; Zhang L; Lou Y; Qiu Y
Biomed Pharmacother; 2021 Jan; 133():110996. PubMed ID: 33227712
[TBL] [Abstract][Full Text] [Related]
8. LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2.
Huang N; Guo W; Ren K; Li W; Jiang Y; Sun J; Dai W; Zhao W
Front Oncol; 2019; 9():1103. PubMed ID: 31696057
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-Induced lncRNA-NEAT1 Sustains the Growth of Hepatocellular Carcinoma via Regulation of miR-199a-3p/UCK2.
Zhang Q; Cheng Q; Xia M; Huang X; He X; Liao J
Front Oncol; 2020; 10():998. PubMed ID: 32670881
[No Abstract] [Full Text] [Related]
10. LncRNA NEAT1 Promotes Proliferation, Migration And Invasion Via Regulating miR-296-5p/CNN2 Axis In Hepatocellular Carcinoma Cells.
Li Y; Ding X; Xiu S; Du G; Liu Y
Onco Targets Ther; 2019; 12():9887-9897. PubMed ID: 31819486
[TBL] [Abstract][Full Text] [Related]
11. LncRNA NEAT1/miR-1224/KLF3 contributes to cell proliferation, apoptosis and invasion in lung cancer.
Yu PF; Wang Y; Lv W; Kou D; Hu HL; Guo SS; Zhao YJ
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8403-8410. PubMed ID: 31646570
[TBL] [Abstract][Full Text] [Related]
12. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis.
Liang Y; Song X; Li Y; Chen B; Zhao W; Wang L; Zhang H; Liu Y; Han D; Zhang N; Ma T; Wang Y; Ye F; Luo D; Li X; Yang Q
Mol Cancer; 2020 May; 19(1):85. PubMed ID: 32384893
[TBL] [Abstract][Full Text] [Related]
13. Cancer Fighting SiRNA-RRM2 Loaded Nanorobots.
Sharma A; Kumar P; Ambasta RK
Pharm Nanotechnol; 2020; 8(2):79-90. PubMed ID: 32003677
[TBL] [Abstract][Full Text] [Related]
14. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
[TBL] [Abstract][Full Text] [Related]
15. MYC-regulated lncRNA NEAT1 promotes B cell proliferation and lymphomagenesis via the miR-34b-5p-GLI1 pathway in diffuse large B-cell lymphoma.
Qian CS; Li LJ; Huang HW; Yang HF; Wu DP
Cancer Cell Int; 2020; 20():87. PubMed ID: 32206038
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA NEAT1 promotes colorectal cancer progression by regulating miR-205-5p/VEGFA axis.
Liu H; Li A; Sun Z; Zhang J; Xu H
Hum Cell; 2020 Apr; 33(2):386-396. PubMed ID: 32065361
[TBL] [Abstract][Full Text] [Related]
17. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer.
Gandhi M; Groß M; Holler JM; Coggins SA; Patil N; Leupold JH; Munschauer M; Schenone M; Hartigan CR; Allgayer H; Kim B; Diederichs S
Nat Commun; 2020 Jun; 11(1):3214. PubMed ID: 32587247
[TBL] [Abstract][Full Text] [Related]
18. RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer.
Yang Y; Lin J; Guo S; Xue X; Wang Y; Qiu S; Cui J; Ma L; Zhang X; Wang J
Cancer Cell Int; 2020 Dec; 20(1):587. PubMed ID: 33372599
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Yang PM; Lin LS; Liu TP
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
